MONDAY, OCTOBER 15, 2007

7:45 – 8:30 am

Registration & Continental Breakfast

8:30 – 8:40

Welcome & Opening Remarks

Howard Fillit, MD, Executive Director, ADDF

8:40 – 9:10

Plenary Talk

Jeffrey S. Nye, MD, PhD, Johnson and Johnson Pharmaceutical R&D, LLC

I.  NEUROPROTECTION

Session Chair

Frank Longo, MD, PhD, Stanford University

9:10 – 9:30

The Nrf2 Mediated Pathway as a Therapeutic Target in Alzheimer's Disease

Jari Koistinaho, MD, University of Kuopio

9:30 – 9:50

Novel C-terminal Proteolysis of APP as a Therapeutic Target for Alzheimer’s Disease

Varghese John, PhD, Buck Institute

9:50 – 10:10

Small Molecule p75 NTR and TrkB Ligands for Alzheimer's Disease Therapeutics

Frank Longo, MD, PhD, Stanford University

10:10 – 10:30

Panel Discussion

10:30 – 10:50

Break

10:50 – 11:10

Combinatorial Approaches to Small Molecule NGF Receptor Agonists

Nicholas Webster, PhD, Veterans Medical Research Foundation

11:10 – 11:30

Why Do We Need Novel Multimodal Neuroprotective and Neurorestorative Drugs for Alzheimer's Disease?

Moussa B.H. Youdim, PhD, Technion-Israel Institute of Technology

11:30 – 11:50

Bone Marrow-Mobilizing Agents for Alzheimer's Disease

Juan Sanchez-Ramos, MD, PhD, University of South Florida

11:50 am –  12:10 pm

The CKI Pathway in Age-Related Diseases

Igor Roninson, PhD, Senex Biotechnology, Inc.

12:10 – 12:30

Panel Discussion

12:30 – 2:00

Lunch

II. ANTI-AMYLOID AND MISFOLDING

Session Chair

Michael Wolfe, PhD, Brigham and Women’s Hospital and Harvard Medical School

2:00 – 2:20

Hsp90, Degradation and Tau: Clinical implications of Basic Research

Leonard Petrucelli, PhD, Mayo Clinic

2:20 – 2:40

ApoE Amyloid Connection

Thomas Wisniewski, MD, New York University

2:40 – 3:00

Anti-amyloidogenic Properties of Resveratrol and its Analogues

Philippe Marambaud, PhD, NSLI Jewish Research Inst.

3:00 – 3:20

Commercialization of BRI-based Peptides for the
Treatment of Alzheimer's Disease

Luciano D'Adamio, MD, PhD, Albert Einstein College of Medicine

3:20 – 3:40

Panel Discussion

3:40 – 4:00

Break

4:00 – 4:20

Efficacy of Small Molecule Assembly Blockers

William F. Goure, PhD, Acumen Pharmaceuticals

4:20 – 4:40

Selective Amyloid-lowering Agents

Michael Wolfe, PhD, Brigham and Women’s Hospital and Harvard Medical School

4:40 – 5:00

Panel Discussion

5:00 – 7:00

Networking Reception

TUESDAY, OCTOBER 16, 2007

7:45 – 8:30 am

Continental Breakfast

III. MISFOLDING II

8:30 – 8:50

Plant-based Primary Screen and Animal-based Secondary Screens for Chaperone Inducing Drugs Against Protein Misfolding in Alzheimer's Disease

Pierre Goloubinoff, PhD, University of Lausanne

8:50 – 9:10

Development of Hsp90 Inhibitors as Novel Therapeutics for AD

Gabriela Chiosis, PhD, Memorial Sloan-Kettering Cancer Center

9:10 – 9:30

NADPH Oxidase as a Therapeutic Target in Alzheimer's Disease

Michelle Block, PhD, Virginia Commonwealth University

9:30 – 9:50

Panel Discussion

9:50 – 10:10

Break

IV. ANTI-TANGLES

Session Chair

Eva-Maria Mandelkow, MD, PhD, Max-Planck-Unit for Structural Mol. Biology

10:10 – 10:30

Molecular Targets for Tau Pathology

Eva-Maria Mandelkow, PhD, Max Planck Unit for Structural Biology

10:30 – 10:50

Distal Cis-Elements and Compounds that Regulate Tau Splicing

Jianhua Zhou, PhD, University of Massachusetts Medical School

10:50 – 11:10

p25/Cdk5, the Missing Link to a Reactivation of the Cell Cycle in Neurofibrillary Degeneration

Luc Buee, PhD, French National Institute for Health and Medical Research

11:10 – 11:30

Tau-focused Drug Discovery for
Alzheimer's Disease and Related Tauopathies

John Trojanowski, MD, PhD, University of Pennsylvania

11:30 – 11:50

Allopregnanolone as a Neurogenic and Cognition Enabling Therapeutic for Alzheimer's Disease: Preclinical Evidence

Roberta Brinton, PhD, University of Southern California

11:50 am – 12:10 pm

Panel Discussion

12:10 – 1:10

Lunch

V. IMMUNOLOGY AND ANTI-INFLAMMATION STRATEGIES

Session Chair

D. Martin Watterson, PhD, Northeastern University

1:10 – 1:30

Immune Defects in Alzheimer’s Disease:  New Medications Development

John Cashman, PhD, Human Biomolecular Research Institute

1:30 – 1:50

Small Molecule Modulators of CNS Proinflammatory Cytokine Production

D. Martin Watterson, PhD, Northwestern University

1:50 – 2:10

Agonists of TGFβ Signaling to Treat Alzheimer's Disease

Tony Wyss-Coray, PhD, Stanford University

2:10– 2:30

Panel Discussion

2:30 – 2:50

Break

VI. COGNITIVE ENHANCERS

Session Chair

Antony Horton, PhD, ADDF

2:50 – 3:10

IRAP-a Novel Target for the Development of Memory-Enhancing Agents  

Siew Yeen Chai, PhD, Howard Florey Institute

3:10 – 3:30

Cognitive-enhancing Effects ff Angiotensin IV: An Investigation of Molecular Mechanisms

Paul Gard, PhD, University of Brighton

3:30 – 3:50

Clinical Efficacy of AC-1202 (Ketasyn™) in Mild to Moderate Alzheimer’s Disease

Lauren C. Costantini, PhD, Accera, Inc.

3:50 – 4:10

Panel Discussion

4:10  – 4:20

Closing Remarks

Howard Fillit, MD, ADDF